Uncategorized

Uncategorized

New Releases from NCBI BookshelfBlinatumomab (Blincyto): Indication: For the treatment of patients with Philadelphia chromosome–negative, CD19-positive B-cell precursor acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy: Reimbursement Recommendation [Internet].​Blinatumomab (Blincyto): Indication: For the treatment of patients with Philadelphia chromosome–negative, CD19-positive B-cell precursor acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy: Reimbursement Recommendation [Internet].

Canada’s Drug Agency (CDA-AMC) recommends that Blincyto be reimbursed by public drug plans for the treatment of patients with Philadelphia

Uncategorized

New Releases from NCBI BookshelfRuxolitinib (Opzelura): Indication: For the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 12 years of age and older whose disease is not adequately controlled with conventional topical prescription therapies (topical corticosteroids, topical calcineurin inhibitors) or when those therapies are not advisable: Reimbursement Recommendation [Internet].​Ruxolitinib (Opzelura): Indication: For the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 12 years of age and older whose disease is not adequately controlled with conventional topical prescription therapies (topical corticosteroids, topical calcineurin inhibitors) or when those therapies are not advisable: Reimbursement Recommendation [Internet].

Canada’s Drug Agency (CDA-AMC) recommends that Opzelura should not be reimbursed by public drug plans for the topical treatment of

Uncategorized

New Releases from NCBI BookshelfDaratumumab (Darzalex SC): Indication: Daratumumab in combination with bortezomib, lenalidomide, and dexamethasone, followed by maintenance treatment in combination with lenalidomide, for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant: Reimbursement Recommendation [Internet].​Daratumumab (Darzalex SC): Indication: Daratumumab in combination with bortezomib, lenalidomide, and dexamethasone, followed by maintenance treatment in combination with lenalidomide, for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant: Reimbursement Recommendation [Internet].

Canada’s Drug Agency (CDA-AMC) recommends that Darzalex SC in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) followed by maintenance treatment

Uncategorized

New Releases from NCBI BookshelfVoice Prostheses and Heat and Moisture Exchangers for Adults After Total Laryngectomy: An Updated Rapid Review: Health Technologies [Internet].​Voice Prostheses and Heat and Moisture Exchangers for Adults After Total Laryngectomy: An Updated Rapid Review: Health Technologies [Internet].

Total laryngectomy is a surgical procedure that removes the larynx. During the surgery, the trachea is diverted to an opening

Scroll to Top